Canaccord initiated coverage of Beam Therapeutics (BEAM) with a Buy rating and $74 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Cathie Wood Loads Up on Momentum Stocks after Earnings Rally. Should You Follow?
- Beam Therapeutics Secures Standby License for Key Patents
- Beam Therapeutics announces upcoming board member resignation
- Beam Therapeutics participates in a conference call with William Blair
- Cathie Wood’s ARK Investment buys 116K shares of Beam Therapeutics today